# Ketamine Clinic Marketing Compliance Guide: IV Ketamine for Depression Without Triggering an FDA Letter A practical, claim-by-claim ketamine clinic marketing compliance guide focused on off-label IV ketamine for depression. Covers the FDA October 2023 communication, Spravato vs racemic ketamine framing, REMS context, and the language patterns that survive a regulator review. By RegenCompliance Editorial (FDA/FTC compliance desk). Published 2026-05-19. Reading time 9 minutes. Canonical page: https://regencompliance.ai/blog/ketamine-clinic-marketing-compliance-guide Ketamine clinic marketing for depression sits in a narrow, well-mapped regulatory corridor. The FDA issued an October 2023 public communication specifically about compounded ketamine products marketed for psychiatric disorders. The FTC has separate substantiation rules for outcome and testimonial language. State medical boards and the DEA are watching prescribing behavior. The good news: the patterns regulators care about are repetitive, and you can rewrite around them without losing the marketing message. This guide focuses tightly on the IV racemic-ketamine for depression use case - the dominant ketamine clinic offering - and walks through five compliance pitfalls and the rewrites that work in 2026. It is the practical companion to our broader [ketamine clinic marketing compliance overview](https://regencompliance.ai/blog/ketamine-clinic-marketing-compliance) and is meant to be read with your live website open in another tab. The October 2023 FDA communication The FDA publicly stated that compounded ketamine products marketed for psychiatric disorders are not FDA-approved and that certain marketing patterns - safety overstatement, at-home use without supervision, equivalence to FDA-approved esketamine - create patient risk. That communication is the benchmark agency staff are reading current ketamine clinic marketing against. ## Pitfall 1: Conflating racemic ketamine with Spravato Spravato (esketamine), the intranasal product from Janssen, is FDA-approved for treatment-resistant depression and major depressive disorder with acute suicidal ideation, under a Risk Evaluation and Mitigation Strategy (REMS) program. Racemic ketamine, the molecule used in most IV ketamine clinics, is FDA-approved as an anesthetic - not as a psychiatric therapy. They are not the same product, not the same legal status, and not the same risk profile. Non-compliant “We offer the same proven depression treatment that the FDA approved in 2019 - delivered in a more comfortable IV format.” Compliant alternative “Esketamine (Spravato) is FDA-approved for certain forms of depression under a REMS program; the IV ketamine our clinic provides is an off-label use of an FDA-approved anesthetic, prescribed at the clinician's discretion and not subject to the same FDA approval or REMS.” Why: The bad version implies the IV product carries the FDA approval that actually belongs to a different, intranasal, manufactured drug. That is the equivalence pattern called out in the FDA October 2023 communication. ## Pitfall 2: Disease cure and outcome guarantee language Depression, PTSD, anxiety, and chronic pain are diagnosable medical conditions. Claiming to *cure*, *treat*, or *reverse* them with ketamine triggers FDA disease-claim rules on top of FTC substantiation requirements (see the [FTC Health Products Compliance Guidance](https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance)). The phrase treatment-resistant depression is particularly sharp because it is the labeled indication for Spravato but not for racemic ketamine. Non-compliant “Cure your treatment-resistant depression in 6 sessions - guaranteed results or your money back.” Compliant alternative “Some patients with depression that has not responded to first-line therapies report meaningful symptom relief during a course of IV ketamine. Response rates and durability vary; our clinical team will discuss the published literature and the limits of the evidence during your consultation.” Why: The bad version cures a labeled diagnosis (disease claim), uses a Spravato-coded indication phrase, and adds a money-back outcome guarantee. The compliant version describes the same offer using subjective-report language and acknowledges variability. ## Pitfall 3: Safety overstatement Ketamine has a defined adverse-event profile: dissociation, elevated blood pressure, nausea, lower-urinary-tract effects at long-term high dose, and abuse-liability concerns appropriate to a Schedule III controlled substance. Marketing that calls IV ketamine safe, side-effect-free, or non-addictive is contradicted by the labeling and by clinical literature, and is a pattern the FDA specifically flagged. Non-compliant “Ketamine therapy is safe, non-addictive, and has no significant side effects.” Compliant alternative “Ketamine is a Schedule III controlled substance with a known side-effect profile that includes transient dissociation, increases in blood pressure and heart rate, nausea, and abuse potential. Our protocols include monitoring during and after each infusion.” Why: The safe-and-side-effect-free framing is one of the recurring patterns in FDA and state-board action against compounded-ketamine marketing. Honest risk disclosure also builds trust with the patient population you want. ## Pitfall 4: At-home and unsupervised-use framing The FDA October 2023 communication was, in part, a response to the rapid growth of mailed and at-home compounded ketamine offerings that the agency considered to pose unacceptable patient risk. See [FDA drug compounding laws](https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws) for the underlying regulatory framework. If your clinic ships compounded oral or sublingual ketamine for unsupervised home use, the marketing cannot present that as a casual or low-friction service. Non-compliant “Get prescription ketamine delivered to your door - take it whenever you need a reset.” Compliant alternative “At-home oral ketamine is provided only after in-clinic clinical evaluation, by patient-specific prescription where the prescriber has determined supervised in-clinic delivery is not required for this patient. Compounded ketamine is not FDA-approved for any psychiatric indication.” Why: A whenever-you-need-a-reset frame is consumer-product language for a Schedule III controlled substance, and reads exactly like the marketing the FDA called out as creating patient risk. ## Pitfall 5: Transformational testimonial copy Patient testimonials in mental-health marketing are subject to the [FTC Endorsement Guides](https://www.ftc.gov/news-events/news/press-releases/2023/06/federal-trade-commission-announces-updated-advertising-guides-combat-deceptive-reviews-endorsements) - see our [2023 update overview](https://regencompliance.ai/blog/ftc-endorsement-guides-2023-update) - including tightened material-connection and typical-experience disclosure requirements. Dramatic single-patient outcomes presented as representative outcomes - without typical-experience disclosure and without substantiation - are the exact pattern the FTC has actioned in adjacent depression-related marketing. Non-compliant “I had failed every antidepressant for 15 years. After 3 ketamine sessions I am finally free. (typical patient story)” Compliant alternative “One patient described meaningful improvement in mood and function after a course of IV ketamine; clinical response rates in published racemic-ketamine literature vary and many patients do not experience this degree of change. Individual outcomes are not predictive of yours.” Why: The bad version uses a single dramatic outcome as a typical-experience claim. The FTC Endorsement Guides require either typical-experience evidence or clear disclosure that the result is atypical. ## Do and don’t at a glance - **Do** distinguish FDA-approved Spravato from off-label racemic-ketamine in plain language. - **Do** disclose the controlled-substance status, the side-effect profile, and the off-label nature of the use. - **Do** frame patient outcomes as variable and individual, with typical-experience disclosure on testimonials. - **Don’t** use the labeled Spravato indication phrase treatment-resistant depression to describe what your IV ketamine program treats. - **Don’t** use safe, no-side-effects, or non-addictive language for a Schedule III controlled substance. - **Don’t** market at-home or unsupervised ketamine as a low-friction wellness product. Ketamine rules in the scanner RegenCompliance scans ketamine clinic copy for the five patterns above plus the FTC Endorsement Guides 2023 updates relevant to mental-health testimonials and the platform-policy flags that get ketamine campaigns rejected at Google and Meta. [Apply for the founder beta](https://regencompliance.ai/apply) or see all [modalities we cover](https://regencompliance.ai/coverage). ## Adjacent reading Ketamine clinics frequently operate alongside IV nutrient and NAD+ programs. The marketing-language patterns are different but the substantiation framework is shared. Practices also offering therapy or psychiatry services should see [mental health practice marketing compliance](https://regencompliance.ai/blog/mental-health-practice-marketing-compliance) for the parallel rules. For NAD+, see our note on the FDA position around [NAD+ IV therapy marketing](https://regencompliance.ai/blog/nad-iv-therapy-marketing-fda-position) for the parallel. Key Takeaways - Racemic IV ketamine is an off-label use of an FDA-approved anesthetic; it is not the same product as FDA-approved Spravato and should never be marketed as if it were. - The FDA October 2023 public communication is the current enforcement benchmark; safety overstatement, at-home framing, and equivalence claims are the specific patterns called out. - Cures depression, treatment-resistant depression, safe, no side effects, and non-addictive are five high-risk phrases to remove from ketamine clinic marketing. - Patient testimonials in this category fall under the FTC Endorsement Guides 2023 update; typical-experience disclosure and material-connection disclosure are not optional. - Disclose the controlled-substance status, the off-label use, and the side-effect profile in lead-level copy, not in 10-point footnotes. --- RegenCompliance is FDA/FTC compliance scanning software for healthcare marketing, operated by Regen Portal LLC. Educational compliance tool, not legal advice. Not affiliated with the FDA or FTC. Contact: support@regencompliance.ai. Full site index for AI agents: https://regencompliance.ai/llms.txt